The world of psychedelic research has taken another significant step forward. On 7th July 2026, Compass Pathways announced encouraging new data from its second ongoing Phase 3 clinical trial investigating COMP360, a proprietary synthetic formulation of psilocybin, as a treatment…
With temperatures climbing across the UK once again, many researchers are turning their attention to an often-overlooked factor that can significantly affect their projects: temperature control. While warmer weather may be great for spending time outdoors, it can create challenges…
Researchers have published the results of a new randomised clinical trial investigating whether psilocybin-assisted therapy could help people living with cocaine use disorder. The study, published in JAMA Network Open, adds to a growing body of research exploring the potential…
As life expectancy continues to rise, scientists are increasingly focused on a different question: how can we age well? While modern medicine has helped people live longer, age-related cognitive decline, memory loss and neurodegenerative conditions such as Alzheimer’s disease remain…
Researchers from the Karolinska Institute in Sweden have found that a single dose of psilocybin, combined with psychological support, produced rapid reductions in depressive symptoms in people living with major depressive disorder. Some participants reported improvements within just a few days, with benefits continuing for several months afterwards.
New research published in Nature Communications suggests a single dose of psilocybin may lead to lasting structural brain changes. Explore what this means for neuroplasticity and mental health.
Scientists have engineered a tobacco plant to produce five different psychedelic compounds at once — combining genes from plants, mushrooms, and even toads. It’s a breakthrough that could reshape how these compounds are produced, but it also raises bigger questions about where this technology is heading.
Interest in Psilocybin is growing as researchers explore its potential effects on complex neurological conditions like Multiple Sclerosis (MS) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. While no clinical trials have directly tested psilocybin in these conditions, early research in related areas; such as chronic pain, post-viral illness, and neuroinflammation; is beginning to highlight mechanisms that may be relevant. From its influence on brain connectivity to its potential role in modulating inflammation, psilocybin is emerging as a compound of scientific interest, though much more research is needed to understand its true impact.
If you have ever searched for magic mushroom strains, you have likely seen bold claims promising specific effects — more visuals, deeper introspection, higher energy or stronger potency.
Disclaimer Psilocybin mushrooms are Class A substances in the UK, and it is illegal to cultivate or germinate psilocybin spores. All spores sold by OnlySpores are intended for microscopy and research purposes only. The Fascinating World of Spore Microscopy Studying psilocybin spores under…
